Broeckelmann, Paul J., Goergen, Helen, Fuchs, Michael, Kriz, Jan, Semrau, Robert, Baues, Christian, Kobe, Carsten, Behringer, Karolin, Eichenauer, Dennis A., von Tresckow, Bastian, Klimm, Beate, Halbsguth, Teresa, Wongso, Diana, Pluetschow, Annette, Haverkamp, Heinz ORCID: 0000-0001-6895-4132, Dietlein, Markus, Eich, Hans T., Stein, Harald, Diehl, Volker, Borchmann, Peter and Engert, Andreas (2015). Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group. Br. J. Haematol., 171 (4). S. 547 - 557. HOBOKEN: WILEY. ISSN 1365-2141

Full text not available from this repository.

Abstract

Accurate clinical staging is crucial for adequate risk-adapted treatment in Hodgkin lymphoma (HL) to prevent patients from under- or over-treatment. Within the latest German Hodgkin Study Group trial generation, diagnostic findings such as histopathology, computerized tomography imaging and clinical risk factors were re-evaluated by expert panels. Here, we retrospectively analysed 5965 patients and identified 399 in who major discordant findings changed their first-line treatment allocation. Histopathology review did not confirm the initial diagnosis of HL in 87 patients. Treatment allocation was revised in 312 of the remaining 5878 patients: 176 were assigned to a higher and 128 to a lower risk group, respectively; the correct treatment group remained unclear in 8 patients. Cases of revised treatment allocation accounted for 9.8%, 6.0%, 0.8%, and 14.8% of patients initially assigned to the HD13, HD14, HD15 trials and stage IA lymphocyte-predominant HL project, respectively. Most revisions were due to wrong application of clinical stage (20.5% of 312 patients with revised treatment group), histological subtype (9.0%) or the risk factors 3 involved areas (46.8%) or large mediastinal mass (9.3%). In conclusion, centralized review by experienced experts changed risk-adapted first-line treatment in a relevant proportion of HL patients. Quality control measures clearly improve the accuracy of treatment and should be implemented in clinical practice.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Broeckelmann, Paul J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goergen, HelenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuchs, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kriz, JanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Semrau, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baues, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kobe, CarstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Behringer, KarolinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eichenauer, Dennis A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Tresckow, BastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klimm, BeateUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Halbsguth, TeresaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wongso, DianaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pluetschow, AnnetteUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haverkamp, HeinzUNSPECIFIEDorcid.org/0000-0001-6895-4132UNSPECIFIED
Dietlein, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eich, Hans T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stein, HaraldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Diehl, VolkerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borchmann, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Engert, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-388198
DOI: 10.1111/bjh.13646
Journal or Publication Title: Br. J. Haematol.
Volume: 171
Number: 4
Page Range: S. 547 - 557
Date: 2015
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1365-2141
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
POSITRON-EMISSION-TOMOGRAPHY; INVOLVED-FIELD RADIOTHERAPY; MALIGNANT-LYMPHOMA; ASSURANCE PROGRAM; FDG PET; DISEASE; CANCER; TRIAL; MULTICENTER; CLASSIFICATIONMultiple languages
HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/38819

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item